ELEV
Elevation Oncology
ELEV
ELEV
Delisted
ELEV was delisted on the 22nd of July, 2025.
27 hedge funds and large institutions have $21.5M invested in Elevation Oncology in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less ownership
Funds ownership: →
54% less capital invested
Capital invested by funds: $47.2M → $21.5M (-$25.6M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Holders
27
Holding in Top 10
3
Calls
–
Puts
–
Top Buyers
| 1 | +$326K | |
| 2 | +$190K | |
| 3 | +$140K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$34.6K |
| 5 |
VF
Virtu Financial
New York
|
+$31K |
Top Sellers
| 1 | -$3.96M | |
| 2 | -$1.3M | |
| 3 | -$1.25M | |
| 4 |
VP
venBio Partners
San Francisco,
California
|
-$1.04M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$142K |